Drugs / Helium-3
Helium-3
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02748798 | Nov 2020 → Oct 2021 | asbestosis, asthma, bronchiectasis, common cold +9 | Thunder Bay Regional Health Research Institute | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00846014 | Jan 2009 → Aug 2011 | acute asthma | University of Massachusetts, Worcester | Withdrawn | No outcome recorded |
| — | NCT00846573 | Nov 2008 → Apr 2011 | asthma, chronic obstructive pulmonary disease, cystic fibrosis | University of Massachusetts, Worcester | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Helium-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00846014 ↗ |
| Known as | HP 3He | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02748798 ↗ |
| Known as | Hyperpolarized Helium-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00846573 ↗ |
| Modality | Diagnostic / imaging agent | “to produce lung images” NCT00846014 ↗ |
| Route | Inhaled | “breath in individual 1 liter bags of gas” NCT00846014 ↗ |